Table 4.

Distributional changes of neuroendocrine enterochromaffin‐like hyperplasia types and serum chromogranin A levels at the two gastroscopy examinations

High CgA (n = 11)	Archived gastroscopy samples	Recent gastroscopy	P‐value
Chromogranin A‐specific immunohistochemistry
Negative	8 (72.7%)	2 (18.2%)	0.0192
Diffuse ECL hyperplasia	0 (0%)	5 (45.4%)
Linear ECL hyperplasia	2 (18.2%)	2 (18.2%)
Micronodular ECL hyperplasia	1 (9.1%)	2 (18.2%)
Serum chromogranin A (ng/mL)
Patients with histological change (n = 6)†	411.75 ± 469.88 (161.00–327.05)	713.53 ± 766.97 (233.05–767.15)	0.0316
Patients without histological change (n = 4)	197.53 ± 131.31 (120.83–219.9)	164.68 ± 67.82 (128.43–178.85)	0.3752

Unit of enterochromaffin‐like (ECL) hyperplasia data is the number of observations. Mean ± standard deviation (interquartile range). ^†One patient from the group had no serum chromogranin A (CgA) measurement around the time of archive gastroscopy results. P‐values of statistically different results between the two cohorts are indicated with bold text. [Correction added on 18 May 2020, after first online publication: A missing number of observation has been inserted.]